Phase 3 N=3,395 Recommendations of Enhanced Recovery Interventions for Patient's Clinical Team and Collection of Associated Data
Perioperative Optimization
Primary: 30 Day Hospital Free Days — 27; 27; 26; 27 Number of hospital free days
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=463 A Clinical Trial to Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia
Schizophrenia
Primary: Change From Baseline in PANSS Total Score at Week 6 — -19.3; -16.9; -19.6 score on a scale — p=0.886
Phase 3 N=35 Study to Evaluate an 8 mg Aflibercept (EYLEA®) Prefilled Syringe (PFS)
Diabetic Macular Edema (DME) · Neovascular Age-Related Macular Degeneration (nAMD)
Primary: Number of 8 mg Aflibercept Injections Successfully Administered Utilizing the PFS — 35 injections
Phase 3 N=708 Active Controlled Trial of CHF5993 Pressurized Metered-dose Inhaler ( pMDI) vs Symbicort®Turbuhaler® in Patients With Chronic Obstructive Pulmonary Disease ( COPD) (TRIVERSYTI)
COPD (Chronic Obstructive Pulmonary Disease)
Primary: Change From Baseline in Pre-dose Forced Expiratory Volume Within the First Second (FEV1) at Week 24 — 0.030; -0.032 Liters — p=< 0.001
Phase 3 N=69 An Open-label Study to Investigate the Clinical Efficacy of Different Dosing Regimens of Efgartigimod IV in Patients With Generalized Myasthenia Gravis
Generalized Myasthenia Gravis · MG - Myasthenia Gravis · gMG
Primary: Mean of the Average MG-ADL Total Score Change From Baseline During the Visit of Week 1 Through Week 21 by Regimen Arm — -5.13; -4.61 Score on a scale
Phase 3 N=509 Clinical Study to Evaluate PRO-169 for Diabetic Macular Edema
Diabetic Macular Edema
Primary: Best Corrected Visual Acuity — 4.89; 5.55; 7.09; 7.71 Letters
Phase 3 N=589 A Study to Evaluate the Efficacy and Safety of Adjunctive Troriluzole in Obsessive-Compulsive Disorder
Obsessive-Compulsive Disorder
Primary: Change From Baseline in the Y-BOCS Total Score in the Baseline Y-BOCS ≥24 Stratification Cohort at Week 8 (Negative Change Indicates Symptom Improvement) — -3.62; -4.59…
Phase 3 N=241 A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis
Atopic Dermatitis
Primary: Percentage of Participants Achieving a ≥75% Improvement in the Eczema Area and Severity Index Score (EASI75) at Week 8 — 18.5; 70.0 percentage of participants — p=<0.0001
Phase 3 N=50 Opiate Suicide Study in Patients With Major Depression
Major Depressive Disorder
Primary: Change in Scale for Suicidal Ideation (SSI) Total Scores Will be Analyzed as the Primary Outcome Measure Using Mixed Effects Models, — 15.2; 15.0; -11.3; -7.7 score on a…
Phase 3 N=1,414 A Study to Learn About Zavegepant as the Acute Treatment of Migraine in Asian Adults
Migraine
Primary: Percentage of Participants With Pain Freedom at 2 Hours Post-dose — 23.2; 14.1 Percentage of participants — p=<0.0001
Phase 3 N=530 Study of Cefepime-zidebactam (FEP-ZID) in Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)
Complicated Urinary Tract Infection · Acute Pyelonephritis
Primary: Percentage of Subjects With Overall Success at Test-of-Cure — 250; 93; 31; 43 Participants
Phase 3 N=277 Anifrolumab Asian PhIII Efficacy Study for Systemic Lupus Erythematosus (SLE)
Active Systemic Lupus Erythematosus
Primary: Difference in Proportion of Participants Who Are Responders Between Anifrolumab and Placebo — 84; 46 Participants — p=>0.999
Phase 3 N=139 A Study of TRS01 in Subjects With Active Non-infectious Anterior Uveitis Including Subjects With Uveitic Glaucoma
Non-infectious Anterior Uveitis · Uveitic Glaucoma
Primary: Anterior Chamber Cell (ACC) Grade = 0 on Day 28 — 38; 32; 44; 15 Participants
Phase 3 N=100 Rivaroxaban vs. Warfarin for Post Cardiac Surgery Atrial Fibrillation
Atrial Fibrillation · Stroke · Bleeding
Primary: Postoperative Length of Stay — 8; 7 days
Phase 3 N=559 Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced NSCLC
Non-Small Cell Lung Cancer
Primary: Overall Survival — 9.4; 10.5 months — p=0.0399